New Drug for Diabetes
Evogliptin, a drug for treatment of type 2 diabetes, licensed last year by South Korean pharmaceutical company Dong-A ST Co, Ltd., will undergo clinical trials in Russia. The trials will be conducted by GEROPHARM. It will be an international phase III multicenter clinical trial. The study is designed according to all international practical requirements and includes “double blinding” (“double blind test”) with double blanks (placebo). The study will involve 11 Russian sites and 27 sites in Korea.
It should be reminded that evogliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4) and belongs to a class of gliptins. They are well-established in clinical practice as safe and effective oral drugs reducing the glucose level in patients with type 2 diabetes. Currently gliptins make over half of global market of oral hypoglycemic drugs. In Russia drugs of that class manufactured by five companies are authorized.
It is planned to launch evogliptin in the Russian market at the end of 2017.